176 related articles for article (PubMed ID: 24631158)
1. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.
Aung KL; Donald E; Ellison G; Bujac S; Fletcher L; Cantarini M; Brady G; Orr M; Clack G; Ranson M; Dive C; Hughes A
J Mol Diagn; 2014 May; 16(3):343-9. PubMed ID: 24631158
[TBL] [Abstract][Full Text] [Related]
2. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
Board RE; Ellison G; Orr MC; Kemsley KR; McWalter G; Blockley LY; Dearden SP; Morris C; Ranson M; Cantarini MV; Dive C; Hughes A
Br J Cancer; 2009 Nov; 101(10):1724-30. PubMed ID: 19861964
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
[TBL] [Abstract][Full Text] [Related]
4. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
[TBL] [Abstract][Full Text] [Related]
5. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
Janku F; Huang HJ; Claes B; Falchook GS; Fu S; Hong D; Ramzanali NM; Nitti G; Cabrilo G; Tsimberidou AM; Naing A; Piha-Paul SA; Wheler JJ; Karp DD; Holley VR; Zinner RG; Subbiah V; Luthra R; Kopetz S; Overman MJ; Kee BK; Patel S; Devogelaere B; Sablon E; Maertens G; Mills GB; Kurzrock R; Meric-Bernstam F
Mol Cancer Ther; 2016 Jun; 15(6):1397-404. PubMed ID: 27207774
[TBL] [Abstract][Full Text] [Related]
6. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Zárate R; Lozano MD; Zubiri L; Perez-Gracia JL; Martín-Algarra S; González A
Clin Chem; 2015 Jan; 61(1):297-304. PubMed ID: 25411185
[TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
8. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
Janku F; Vibat CR; Kosco K; Holley VR; Cabrilo G; Meric-Bernstam F; Stepanek VM; Lin PP; Leppin L; Hassaine L; Poole JC; Kurzrock R; Erlander MG
Oncotarget; 2014 Jun; 5(11):3607-10. PubMed ID: 25003820
[TBL] [Abstract][Full Text] [Related]
10. Detection of cell-free circulating BRAF
Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
[TBL] [Abstract][Full Text] [Related]
11. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Santiago-Walker A; Gagnon R; Mazumdar J; Casey M; Long GV; Schadendorf D; Flaherty K; Kefford R; Hauschild A; Hwu P; Haney P; O'Hagan A; Carver J; Goodman V; Legos J; Martin AM
Clin Cancer Res; 2016 Feb; 22(3):567-74. PubMed ID: 26446943
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies.
Lamy PJ; Castan F; Lozano N; Montélion C; Audran P; Bibeau F; Roques S; Montels F; Laberenne AC
J Mol Diagn; 2015 Jul; 17(4):366-73. PubMed ID: 25952101
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
15. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
Thierry AR; Mouliere F; El Messaoudi S; Mollevi C; Lopez-Crapez E; Rolet F; Gillet B; Gongora C; Dechelotte P; Robert B; Del Rio M; Lamy PJ; Bibeau F; Nouaille M; Loriot V; Jarrousse AS; Molina F; Mathonnet M; Pezet D; Ychou M
Nat Med; 2014 Apr; 20(4):430-5. PubMed ID: 24658074
[TBL] [Abstract][Full Text] [Related]
17. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
18. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
19. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
Pinzani P; Salvianti F; Cascella R; Massi D; De Giorgi V; Pazzagli M; Orlando C
Clin Chim Acta; 2010 Sep; 411(17-18):1319-24. PubMed ID: 20576522
[TBL] [Abstract][Full Text] [Related]
20. SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.
Stadler J; Eder J; Pratscher B; Brandt S; Schneller D; Müllegger R; Vogl C; Trautinger F; Brem G; Burgstaller JP
PLoS One; 2015; 10(11):e0142273. PubMed ID: 26562020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
